An artificial T-cell immunogen consisting of conserved fragments of different proteins of the SARS-CoV-2 virus and its immunogenic properties were studied in BALB/c mice. To create a T-cell immunogen, we used an approach based on the design of artificial antigens that combine many epitopes from the main proteins of the SARS-CoV-2 virus in the one molecule. The gene of the engineered immunogen protein was cloned as part of the pVAX1 plasmid in two versions: with an N-terminal ubiquitin and without it. The obtained plasmids were analyzed for their ability to provide the synthesis of the immunogen protein in vitro and in vivo. It has been shown that protein product of the created artificial genes is actively processed in HEK293T cells and induces cellular immunity in mice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Planas D, Staropoli I, Porot F, Guivel-Benhassine F, Handala L, Prot M, Bolland WH, Puech J, Péré H, Veyer D, Sève A, Simon-Lorière E, Bruel T, Prazuck T, Stefic K, Hocqueloux L, Schwartz O. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. Med. 2022;3(12):838-847.e3. doi: https://doi.org/10.1016/j.medj.2022.09.010
Yamamoto S, Matsuda K, Maeda K, Horii K, Okudera K, Oshiro Y, Inamura N, Takeuchi JS, Konishi M, Ozeki M, Mizoue T, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, Ohmagari N. Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave. Int. J. Infect. Dis. 2023;128:347-354. doi: https://doi.org/10.1016/j.ijid.2023.01.023
Ekström N, Haveri A, Solastie A, Virta C, Österlund P, Nohynek H, Nieminen T, Ivaska L, Tähtinen PA, Lempainen J, Jalkanen P, Julkunen I, Palmu AA, Melin M. Strong Neutralizing Antibody Responses to SARS-CoV-2 Variants Following a Single Vaccine Dose in Subjects With Previous SARS-CoV-2 Infection. Open Forum Infect. Dis. 2022;9(12):ofac625. doi: https://doi.org/10.1093/ofid/ofac625
Wang H, Yuan Y, Wu B, Xiao M, Wang Z, Diao T, Zeng R, Chen L, Lei Y, Long P, Guo Y, Lai X, Wen Y, Li W, Cai H, Song L, Ni W, Zhao Y, Ouyang K, Wang J, Wang Q, Liu L, Wang C, Pan A, Li X, Gong R, Wu T. Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents. Front. Med. 2023:1-11. doi: https://doi.org/10.1007/s11684-022-0954-x
Wang Z, Zhao Z, Cui T, Huang M, Liu S, Su X, Li G, Song T, Li W, Zhong N, Xu M, Yang X, Huang W. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants. Emerg. Microbes Infect. 2022;11(1):829-840. doi: https://doi.org/10.1080/22221751.2022.2048969
Sun Z, Wu T, Xie H, Li Y, Zhang J, Su X, Qi H. The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. Vaccines (Basel). 2022;10(7):1103. doi: https://doi.org/10.3390/vaccines10071103
Borgoyakova MB, Karpenko LI, Rudometov AP, Shanshin DV, Isaeva AA, Nesmeyanova VS, Volkova NV, Belenkaya SV, Murashkin DE, Shcherbakov DN, Volosnikova EA, Starostina EV, Orlova LA, Danilchenko NV, Zaikovskaya AV, Pyankov OV, Ilyichev AA. Immunogenic Properties of the DNA Construct Encoding the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. Mol. Biol. 2021;55(6):889-898. doi: https://doi.org/10.1134/S0026893321050046
Kisakov DN, Kisakova LA, Borgoyakova MB, Starostina EV, Taranov OS, Ivleva EK, Pyankov OV, Zaykovskaya AV, Shcherbakov DN, Rudometov AP, Rudometova NB, Volkova NV, Gureev VN, Ilyichev AA, Karpenko LI. Optimization of In vivo Electroporation Conditions and Delivery of DNA Vaccine Encoding SARS-CoV-2 RBD Using the Determined Protocol. Pharmaceutics. 2022;14(11):2259. doi: https://doi.org/10.3390/pharmaceutics14112259
Borgoyakova MB, Karpenko LI, Rudometov AP, Volosnikova EA, Merkuleva IA, Starostina EV, Zadorozhny AM, Isaeva AA, Nesmeyanova VS, Shanshin DV, Baranov KO, Volkova NV, Zaitsev BN, Orlova LA, Zaykovskaya AV, Pyankov OV, Danilenko ED, Bazhan SI, Shcherbakov DN, Taranin AV, Ilyichev AA. Self-Assembled Particles Combining SARS-CoV-2 RBD Protein and RBD DNA Vaccine Induce Synergistic Enhancement of the Humoral Response in Mice. Int. J. Mol. Sci. 2022;23(4):2188. doi: https://doi.org/10.3390/ijms23042188
Reguzova A, Antonets D, Karpenko L, Ilyichev A, Maksyutov R, Bazhan S. Design and evaluation of optimized artificial HIV-1 poly-T cell-epitope immunogens. PLoS One. 2015;10(3):e0116412. doi: https://doi.org/10.1371/journal.pone.0116412
Andersson HA, Barry MA. Maximizing antigen targeting to the proteasome for gene-based vaccines. Mol. Ther. 2004;10(3):432-446. doi: https://doi.org/10.1016/j.ymthe.2004.05.035
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 175, No. 6, pp. 767-772, June, 2023
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Borgoyakova, M.B., Karpenko, L.I., Rudometov, A.P. et al. Artificial COVID-19 T-Cell Immunogen. Bull Exp Biol Med 175, 804–809 (2023). https://doi.org/10.1007/s10517-023-05951-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-023-05951-7